GlassScriptPhysician profile
Joann Ikard
NPI 1669646329
$19,021.90
in general payments reported to CMS, 2019-2025
27 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,171 · 2022: $2,711 · 2023: $2,748 · 2024: $2,698 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,132 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,132.19 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $7,176.97 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $2,460.15 | 2021-2025 | |
| Genzyme Corporation | $1,501.48 | 2021-2025 | |
| Janssen Biotech, INC. | $1,346.86 | 2021-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $1,218.95 | 2022-2024 | Sotyktu |
| Abbvie INC. | $908.54 | 2021-2023 | |
| Amgen INC. | $816.64 | 2021-2025 | Otezla |
| Ucb, INC. | $625.58 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $396.24 | 2021-2025 | Epsolay, Nemluvio, Aklief |
| Pfizer INC. | $347.57 | 2021-2025 | |
| Incyte Corporation | $326.68 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $320.96 | 2021-2025 | Ebglyss |
| Dermavant Sciences, INC. | $287.65 | 2022-2024 | Vtama |
| Leo Pharma INC. | $240.82 | 2022-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $195.09 | 2021-2023 | Winlevi, Absorica Ld |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $158.34 | 2024-2025 | Acthar |
| Arcutis Biotherapeutics, INC. | $123.06 | 2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $113.76 | 2024 | Ycanth |
| Epi Health, LLC | $113.60 | 2022 | |
| Janssen Scientific Affairs, LLC | $113.56 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $62.55 | 2021 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Genentech USA, INC. | $46.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.62 | 2024 | Farxiga |
| Paratek Pharmaceuticals, INC. | $15.29 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.70 | 2023 | Xifaxan |
| Journey Medical Corporation | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Ikard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.